20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791
3111 – WWW.WHO.INT
Ref. RPQ/REG/ISF/Alert N°6/2021 4 November 2021
Medical Product Alert N°6/2021
Falsified Pfizer-BioNTech COVID-19 Vaccine identified in WHO region of the
Eastern Mediterranean
Alert Summary
This WHO Medical Product Alert refers to one lot of falsified Pfizer-BioNTech COVID-19 Vaccine identified in
the Islamic Republic of Iran and reported to WHO in October 2021. The genuine manufacturer of Pfizer-
BioNTech COVID-19 Vaccine has confirmed that the product listed in this Alert is falsified. The falsified product
was reported at patient level outside authorized and regulated supply chains and authorized vaccination
programmes in the Islamic Republic of Iran.
Genuine Pfizer-BioNTech COVID-19 Vaccine is indicated for active immunization to prevent COVID-19 caused
by SARS-CoV-2 virus. The use of genuine COVID-19 vaccines should be in accordance with official guidance
from national regulatory authorities.
Falsified COVID-19 vaccines pose a serious risk to global public health and place an additional burden on
vulnerable populations and health systems. The risk to patient health from falsified COVID-19 vaccines includes
exposure to unknown and unsafe substances as well as delayed immunization against COVID-19, and could
be life threatening in some circumstances. It is important to detect and remove these falsified Pfizer-BioNTech
COVID-19 Vaccines from circulation to prevent harm to patients.
The products identified in this Alert are confirmed as falsified on the basis that they deliberately / fraudulently
misrepresent their identity, composition or source:
• The product label and artwork are inconsistent with genuine Pfizer-BioNTech COVID-19 Vaccines
• The expiry date on the labels (09/2021) is falsified and inconsistent with the expiry date on genuine
Pfizer-BioNTech COVID-19 Vaccine Lot EH9899
Advice to regulatory authorities and the public
WHO requests increased vigilance within supply chains of countries and regions likely to be affected by these
falsified products. Increased vigilance should include hospitals, clinics, health centres, wholesalers, distributors,
pharmacies and any other suppliers of medical products.
All medical products must be obtained from authorized/licensed suppliers. The products’ authenticity and
physical condition should be carefully checked. Seek advice from a healthcare professional in case of doubt.
If you are in possession of the above falsified products, please do not use them.
If you have used these products, or you suffered an adverse reaction/event having used these products, you
are advised to seek immediate medical advice from a qualified healthcare professional, and to report the incident
to the National Regulatory Authorities / National Pharmacovigilance Centre.
National regulatory / health authorities are advised to immediately notify WHO if these falsified products are
discovered in their country. If you have any information concerning the manufacture, distribution, or supply of
these products, please contact rapidalert@who.int
No comments:
Post a Comment